CA2686033A1 - Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof - Google Patents

Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof Download PDF

Info

Publication number
CA2686033A1
CA2686033A1 CA002686033A CA2686033A CA2686033A1 CA 2686033 A1 CA2686033 A1 CA 2686033A1 CA 002686033 A CA002686033 A CA 002686033A CA 2686033 A CA2686033 A CA 2686033A CA 2686033 A1 CA2686033 A1 CA 2686033A1
Authority
CA
Canada
Prior art keywords
methylpyrrolidine
methyl
tartrate
pyrrolidin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002686033A
Other languages
English (en)
French (fr)
Inventor
Michael Christie
Joseph J. Petraitis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2686033A1 publication Critical patent/CA2686033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Catalysts (AREA)
CA002686033A 2007-05-03 2008-05-02 Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof Abandoned CA2686033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92735607P 2007-05-03 2007-05-03
US60/927,356 2007-05-03
PCT/US2008/005702 WO2008137087A1 (en) 2007-05-03 2008-05-02 Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof

Publications (1)

Publication Number Publication Date
CA2686033A1 true CA2686033A1 (en) 2008-11-13

Family

ID=39688886

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002686033A Abandoned CA2686033A1 (en) 2007-05-03 2008-05-02 Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof

Country Status (14)

Country Link
EP (1) EP2152669A1 (enExample)
JP (1) JP5698887B2 (enExample)
KR (1) KR20100017565A (enExample)
CN (1) CN101679237A (enExample)
AU (1) AU2008248168B2 (enExample)
BR (1) BRPI0810330A2 (enExample)
CA (1) CA2686033A1 (enExample)
EA (1) EA019031B1 (enExample)
IL (1) IL201627A (enExample)
MX (1) MX2009011787A (enExample)
NZ (1) NZ580948A (enExample)
UA (1) UA99913C2 (enExample)
WO (1) WO2008137087A1 (enExample)
ZA (1) ZA200907643B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574873A (en) 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
ES2479440T3 (es) * 2008-01-30 2014-07-24 Cephalon, Inc. Derivados de piridazina sustituidos que tienen actividad antagonista de histamina H3
US10259794B2 (en) * 2014-12-23 2019-04-16 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
KR20210057032A (ko) * 2018-09-07 2021-05-20 사노피 메틸 6-(2,4-디클로로페닐)-5-[4-[(3s)-1-(3-플루오로프로필)피롤리딘-3-일]옥시페닐]-8,9-디히드로-7h-벤조[7]아눌렌-2-카르복실레이트의 염 및 이의 제조 방법

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3329974A1 (de) 1983-08-19 1985-02-28 Bayer Ag, 5090 Leverkusen Herstellung von hydrierten nitrilkautschuken
DE3433392A1 (de) 1984-09-12 1986-03-20 Bayer Ag, 5090 Leverkusen Hydrierung nitrilgruppenhaltiger ungesaettigter polymerer
FR2714849B1 (fr) 1994-01-13 1996-04-05 Inst Francais Du Petrole Procédé de préparation d'un catalyseur d'hydrogénation soluble en phase liquide organique.
DE4403479A1 (de) 1994-02-04 1995-08-10 Basf Ag Verfahren zur Herstellung von Hydroxylammoniumsalzen
WO2004024707A2 (en) * 2002-09-16 2004-03-25 Abbott Laboratories Process for preparing amine type substituted benzofurans
US7153889B2 (en) 2002-11-12 2006-12-26 Abbott Laboratories Bicyclic-substituted amines as histamine-3 receptor ligands
US8110519B2 (en) 2004-03-08 2012-02-07 Japan Science & Technology Agency Polymer-supported metal cluster composition
US7145005B2 (en) 2004-05-12 2006-12-05 Abbott Laboratories 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
CN1960727B (zh) 2004-06-02 2011-02-16 霍夫曼-拉罗奇有限公司 用作组胺-3受体的配体的萘衍生物
US8158652B2 (en) 2004-12-01 2012-04-17 Msd K.K. Substituted pyridone derivative
DE602005026169D1 (de) 2004-12-17 2011-03-10 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CA2595157A1 (en) 2005-01-21 2006-07-27 Schering Corporation Imidazole and benzimidazole derivatives useful as histamine h3 antagonists
EP1866293A1 (en) 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
WO2007048595A1 (en) 2005-10-27 2007-05-03 Ucb Pharma, S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
US7897634B2 (en) 2006-02-09 2011-03-01 Athersys, Inc. Pyrazoles for the treatment of obesity and other CNS disorders
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
WO2008005338A1 (en) 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
NZ574873A (en) * 2006-07-25 2012-03-30 Cephalon Inc Pyridazinone derivatives as h3 inhibitors

Also Published As

Publication number Publication date
IL201627A (en) 2014-06-30
ZA200907643B (en) 2014-03-26
KR20100017565A (ko) 2010-02-16
AU2008248168B2 (en) 2013-03-21
BRPI0810330A2 (pt) 2014-10-14
MX2009011787A (es) 2009-11-13
UA99913C2 (ru) 2012-10-25
AU2008248168A1 (en) 2008-11-13
EA019031B1 (ru) 2013-12-30
JP5698887B2 (ja) 2015-04-08
EP2152669A1 (en) 2010-02-17
JP2010526142A (ja) 2010-07-29
NZ580948A (en) 2011-04-29
CN101679237A (zh) 2010-03-24
EA200971019A1 (ru) 2010-04-30
WO2008137087A1 (en) 2008-11-13
IL201627A0 (en) 2010-05-31

Similar Documents

Publication Publication Date Title
US20100121055A1 (en) Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
JP6491393B2 (ja) ヒストン脱アセチル化酵素6阻害剤としての1,3,4−オキサジアゾール誘導体化合物及びこれを含有する薬剤学的組成物
JP6392888B2 (ja) ヒストン脱アセチル化酵素6阻害剤としての新規化合物およびこれを含む薬剤学的組成物
RU2351589C2 (ru) Производные n-[фенил(алкилпиперидин-2-ил)метил]бензамида и их применение в терапии
CN111770918B (zh) Trpc6的抑制剂
AU2021308344B2 (en) Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
JP2016524597A (ja) 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物
JP2012519196A (ja) スルホニル化されたテトラヒドロアゾロピラジンおよびその医薬としての使用
ZA200603861B (en) Use of tricyclic compounds as glycine transport inhibitors
CA2686033A1 (en) Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
KR20100093103A (ko) 고지혈증 또는 동맥경화증과 같은 질환의 치료에 유용한 cετρ 억제제로서의 1,2-이치환된 4-벤질아미노-피롤리딘 유도체
KR20230158007A (ko) 항바이러스 화합물
CA2791431A1 (en) Derivatives of aminoindanes, their preparation and their application in therapeutics
ZA200407414B (en) Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially CCR5).
Wallace et al. Development of a fit-for-purpose large-scale synthesis of an oral PARP inhibitor
CN114728177A (zh) 作为Kv1.3钾Shaker通道阻滞剂的芳基杂二环化合物
García‐Mingüens et al. Nitroprolinates as Nucleophiles in Michael‐type Additions and Acylations. Synthesis of Enantiomerically Enriched Fused Amino‐pyrrolidino‐[1, 2‐a] pyrazinones and‐diketopiperazines
JP2010526142A5 (enExample)
Vega-Penaloza et al. Stereoselective synthesis of chiral pyrrolidine derivatives of (+)-α-pinene containing a β-amino acid moiety
ZA200700950B (en) Pyrrole derivatives, their preparation and their therapeutic use
CN101142180A (zh) 作为组胺h3受体拮抗剂的吡咯烷衍生物
Shen et al. Asymmetric Synthesis of γ-Amino-Functionalised Vinyl Sulfones: De Novo Preparation of Cysteine Protease Inhibitors
KR20230164136A (ko) Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴 헤테로시클릭 화합물
AU2005252178A1 (en) Histamine H3 receptor agents, preparation and therapeutic uses
JP7672386B2 (ja) オレキシン受容体調節薬としての(2h-1,2,3-トリアゾール-2-イル)フェニル化合物の改善された合成方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130319

FZDE Discontinued

Effective date: 20160504